Johnson & Johnson (NYSE:JNJ) Shares Down 1.6% – Here’s Why

Shares of Johnson & Johnson (NYSE:JNJ) fell 1.6% during trading on Monday . The stock traded as low as $229.53 and last traded at $230.5120. 7,745,479 shares were traded during trading, a decline of 10% from the average session volume of 8,635,934 shares. The stock had previously closed at $234.18.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Phase 3 data and 120?week open?label results for IMAAVY (nipocalimab?aahu) show durable disease control in antibody?positive generalized myasthenia gravis—strengthens J&J’s neurology portfolio and supports longer?term revenue potential for a high?value specialty drug. IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
• Positive Sentiment: CE Mark approval for the new ETHICON 4000 surgical stapler opens/expands access in Europe for a next?generation medtech product—potential to drive consumables/procedural revenue in Ethicon’s franchise. Johnson-Johnson Announces CE-Mark Approval for the New ETHICON™ 4000 Stapler
• Positive Sentiment: New AI?powered CARTOSOUND SONATA module and expanded electrophysiology data broaden J&J’s cardiac device portfolio—could improve competitive positioning and add recurring procedure?related revenue over time. Johnson & Johnson’s AI Cardiac Tools Add Detail To Valuation Story
• Positive Sentiment: Guggenheim raised JNJ’s price target and kept a Buy—analyst upgrade reflects modeled upside from Icotyde and helps sentiment/flows into the stock. Guggenheim Raises Johnson & Johnson (JNJ) Target on Icotyde Upside, Keeps Buy Rating
• Positive Sentiment: High?profile endorsements and media attention (e.g., Jim Cramer) are driving retail/investor interest, which can boost near?term demand for the shares. Jim Cramer Ditches Hot AI Stocks for Johnson & Johnson (JNJ) — Here’s Why
• Neutral Sentiment: J&J will host a fireside chat at the RBC Healthcare Conference (May 19), giving management a platform to update analysts and potentially influence short?term guidance/estimates. Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
• Neutral Sentiment: Analyst/market coverage pieces (Zacks and others) note investor attention on JNJ; these summaries can amplify headlines but add little new fundamental information. Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Dividend coverage mentions J&J among dividend growers—supportive for income investors but not a near?term price catalyst. 3 Giant Dividend Stocks Raising Payouts With Yields Up to 4%
• Negative Sentiment: Technical and momentum headwinds: the share price sits below the 50?day moving average, which can pressure near?term performance and constrain gains until momentum reverses.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on JNJ. Morgan Stanley set a $283.00 price objective on Johnson & Johnson in a research note on Wednesday, April 15th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $265.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 15th. Citigroup upped their price target on Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $252.48.

Johnson & Johnson Stock Performance

The company has a market capitalization of $544.21 billion, a price-to-earnings ratio of 26.12, a P/E/G ratio of 2.26 and a beta of 0.34. The stock has a 50 day simple moving average of $241.08 and a 200 day simple moving average of $218.04. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.75% and a net margin of 21.83%.The business’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be issued a $1.34 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio is 61.97%.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,142 shares of company stock valued at $7,360,528 over the last three months. 0.16% of the stock is currently owned by company insiders.

Institutional Trading of Johnson & Johnson

Several hedge funds have recently added to or reduced their stakes in the business. Auto Owners Insurance Co grew its position in Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after buying an additional 69,108,368 shares in the last quarter. Norges Bank bought a new stake in shares of Johnson & Johnson during the 4th quarter worth about $6,924,523,000. Capital World Investors acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $2,005,942,000. Diamant Asset Management Inc. boosted its holdings in shares of Johnson & Johnson by 24,436.5% in the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock valued at $109,338,000 after acquiring an additional 4,454,778 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after acquiring an additional 3,731,074 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.